The study demonstrates cross-resistance to CDDP through antioxidant defense mechanisms, but it's unclear if this extends to other chemotherapy classes or what factors determine resistance breadth. This knowledge gap limits understanding of treatment sequence strategies in resistant urothelial carcinoma. Gap type: open_question Source paper: IDH2 stabilizes HIF-1α-induced metabolic reprogramming and promotes chemoresistance in urothelial cancer. (2023, EMBO J, PMID:36637036)
Landscape Summary: What determines whether IDH2-mediated metabolic reprogramming confers cross-resistance to other chemotherapeutics beyond CDDP? is a 0.79 priority gap in cancer-biology. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
What determines whether IDH2-mediated metabolic reprogramming confers cross-resistance to other chemotherapeutics beyond CDDP? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: